Jacobs & Co. CA Reduces Stock Holdings in GSK plc (NYSE:GSK)

Jacobs & Co. CA reduced its stake in GSK plc (NYSE:GSKFree Report) by 2.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 145,720 shares of the pharmaceutical company’s stock after selling 4,429 shares during the period. Jacobs & Co. CA’s holdings in GSK were worth $6,247,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc increased its stake in GSK by 2,816.7% in the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 676 shares during the last quarter. BKM Wealth Management LLC purchased a new position in GSK in the fourth quarter valued at approximately $32,000. Richardson Financial Services Inc. purchased a new position in GSK in the fourth quarter valued at approximately $40,000. Jones Financial Companies Lllp increased its stake in GSK by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock valued at $48,000 after purchasing an additional 509 shares during the last quarter. Finally, Princeton Global Asset Management LLC increased its stake in GSK by 54.3% in the fourth quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company’s stock valued at $56,000 after purchasing an additional 533 shares during the last quarter. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Stock Performance

Shares of GSK traded down $0.15 during mid-day trading on Tuesday, reaching $40.40. 1,004,377 shares of the company’s stock were exchanged, compared to its average volume of 3,536,718. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The business’s fifty day simple moving average is $42.56 and its 200-day simple moving average is $41.16. GSK plc has a 52-week low of $33.67 and a 52-week high of $45.92. The stock has a market capitalization of $83.73 billion, a PE ratio of 14.69, a price-to-earnings-growth ratio of 1.22 and a beta of 0.66.

GSK (NYSE:GSKGet Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The firm had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. On average, equities research analysts expect that GSK plc will post 4.11 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a dividend of $0.3762 per share. The ex-dividend date is Thursday, May 16th. This is an increase from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a dividend yield of 3.72%. GSK’s dividend payout ratio (DPR) is currently 53.26%.

Analyst Ratings Changes

GSK has been the topic of a number of research reports. The Goldman Sachs Group initiated coverage on shares of GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Finally, Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.00.

Check Out Our Latest Stock Analysis on GSK

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Read More

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.